M 249314
Latest Information Update: 20 Oct 2008
At a glance
- Originator AstraZeneca
- Developer Nonindustrial source
- Class
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pulmonary hypertension
Most Recent Events
- 09 Jun 2000 New profile
- 09 Jun 2000 Preclinical development for Pulmonary hypertension in Canada (PO)